

Eran Kotler

Research Engineer, Genetics

Publications

PUBLICATIONS

- **Deterministic evolution and stringent selection during preneoplasia.** *Nature*
Karlsson, K., Przybilla, M. J., Kotler, E., Khan, A., Xu, H., Karagyzova, K., Sockell, A., Wong, W. H., Liu, K., Mah, A., Lo, Y. H., Lu, B., Houlahan, et al
2023
- **APOBEC3G protects the genome of human cultured cells and mice from radiation-induced damage.** *The FEBS journal*
Britan-Rosich, Y., Ma, J., Kotler, E., Hassan, F., Botvinnik, A., Smith, Y., Moshel, O., Nasereddin, A., Sharma, G., Pikarsky, E., Ross, S., Kotler, M.
2022
- **Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response** *NATURE CANCER*
McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., Kriner, M., Zhou, Z., Hoang, M., Beechem, J., Zoeller, J., Press, M. F., Slamon, et al
2021; 2 (4): 400-+
- **Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.** *Nature cancer*
McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., Kriner, M., Zhou, Z., Hoang, M., Beechem, J., Zoeller, J., Press, M. F., Slamon, et al
2021; 2 (4): 400-413
- **The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.** *Cell*
Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., Ashenberg, O., Cerami, E., Coffey, R. J., Demir, E., Ding, L., Esplin, E. D., Ford, et al
2020; 181 (2): 236-49
- **Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial**
Caswell-Jin, J. L., McNamara, K. L., Dering, J., Chen, H., Dichmann, R., Perez, A., Patel, R., Kotler, E., Zoeller, J. J., Brugge, J. S., Press, M. F., Slamon, D. J., Curtis, et al
AMER ASSOC CANCER RESEARCH.2020
- **Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).** *Nature communications*
Hurvitz, S. A., Caswell-Jin, J. L., McNamara, K. L., Zoeller, J. J., Bean, G. R., Dichmann, R., Perez, A., Patel, R., Zehngebot, L., Allen, H., Bosserman, L., DiCarlo, B., Kennedy, et al
2020; 11 (1): 5824